Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials

Dyslipidemia is one of the most common adverse effects in schizophrenia patients treated with antipsychotics. However, there are no established effective treatments. In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, R-R, Zhang, F-Y, Gao, K-M, Ou, J-J, Shao, P, Jin, H, Guo, W-B, Chan, P K, Zhao, J-P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078852/
https://www.ncbi.nlm.nih.gov/pubmed/26809842
http://dx.doi.org/10.1038/mp.2015.221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078852/
https://www.ncbi.nlm.nih.gov/pubmed/26809842
http://dx.doi.org/10.1038/mp.2015.221

Ejemplares similares